JP2019081811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019081811A5 JP2019081811A5 JP2019040987A JP2019040987A JP2019081811A5 JP 2019081811 A5 JP2019081811 A5 JP 2019081811A5 JP 2019040987 A JP2019040987 A JP 2019040987A JP 2019040987 A JP2019040987 A JP 2019040987A JP 2019081811 A5 JP2019081811 A5 JP 2019081811A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- liquid pharmaceutical
- sodium
- pharmaceutical formulation
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 108010049264 Teriparatide Proteins 0.000 claims 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 1
- 229960005460 teriparatide Drugs 0.000 claims 1
- 229960000338 teriparatide acetate Drugs 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 229940038773 trisodium citrate Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017182611 | 2017-09-22 | ||
| JP2017182611 | 2017-09-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558440A Division JP6577683B2 (ja) | 2017-09-22 | 2018-09-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201121A Division JP6851536B2 (ja) | 2017-09-22 | 2020-12-03 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019081811A JP2019081811A (ja) | 2019-05-30 |
| JP2019081811A5 true JP2019081811A5 (enExample) | 2019-11-14 |
| JP6826140B2 JP6826140B2 (ja) | 2021-02-03 |
Family
ID=65811407
Family Applications (17)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558440A Active JP6577683B2 (ja) | 2017-09-22 | 2018-09-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019008797A Active JP6714738B2 (ja) | 2017-09-22 | 2019-01-22 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019008790A Active JP6585317B2 (ja) | 2017-09-22 | 2019-01-22 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019040987A Active JP6826140B2 (ja) | 2017-09-22 | 2019-03-06 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019041011A Active JP6817358B2 (ja) | 2017-09-22 | 2019-03-06 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057398A Active JP6581741B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057408A Active JP6634175B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057434A Active JP6646173B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057412A Active JP6781790B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057438A Pending JP2019089865A (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019085817A Active JP6825034B2 (ja) | 2017-09-22 | 2019-04-26 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019228968A Active JP6739612B2 (ja) | 2017-09-22 | 2019-12-19 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020053255A Active JP6766286B2 (ja) | 2017-09-22 | 2020-03-24 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020139570A Active JP6818928B2 (ja) | 2017-09-22 | 2020-08-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020201121A Active JP6851536B2 (ja) | 2017-09-22 | 2020-12-03 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020218741A Active JP6977137B2 (ja) | 2017-09-22 | 2020-12-28 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2021036829A Pending JP2021088606A (ja) | 2017-09-22 | 2021-03-09 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558440A Active JP6577683B2 (ja) | 2017-09-22 | 2018-09-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019008797A Active JP6714738B2 (ja) | 2017-09-22 | 2019-01-22 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019008790A Active JP6585317B2 (ja) | 2017-09-22 | 2019-01-22 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Family Applications After (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019041011A Active JP6817358B2 (ja) | 2017-09-22 | 2019-03-06 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057398A Active JP6581741B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057408A Active JP6634175B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057434A Active JP6646173B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057412A Active JP6781790B2 (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019057438A Pending JP2019089865A (ja) | 2017-09-22 | 2019-03-25 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019085817A Active JP6825034B2 (ja) | 2017-09-22 | 2019-04-26 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2019228968A Active JP6739612B2 (ja) | 2017-09-22 | 2019-12-19 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020053255A Active JP6766286B2 (ja) | 2017-09-22 | 2020-03-24 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020139570A Active JP6818928B2 (ja) | 2017-09-22 | 2020-08-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020201121A Active JP6851536B2 (ja) | 2017-09-22 | 2020-12-03 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2020218741A Active JP6977137B2 (ja) | 2017-09-22 | 2020-12-28 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| JP2021036829A Pending JP2021088606A (ja) | 2017-09-22 | 2021-03-09 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200289621A1 (enExample) |
| EP (1) | EP3685849A4 (enExample) |
| JP (17) | JP6577683B2 (enExample) |
| CN (2) | CN116898955A (enExample) |
| CA (1) | CA3075977A1 (enExample) |
| WO (1) | WO2019059302A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| WO2020090174A1 (ja) * | 2018-10-29 | 2020-05-07 | 旭化成ファーマ株式会社 | 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法 |
| JP7240407B2 (ja) * | 2019-09-05 | 2023-03-15 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する無菌注射剤を製造する方法 |
| JP6965474B1 (ja) * | 2019-12-09 | 2021-11-10 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法 |
| EP4079293A4 (en) * | 2019-12-18 | 2024-01-03 | Daewoong Pharmaceutical Co., Ltd. | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrole-3-yl)-n-methylmethaneamine |
| WO2021229835A1 (ja) * | 2020-05-11 | 2021-11-18 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する安定な液状医薬製剤 |
| CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
| CN114031680B (zh) * | 2021-09-01 | 2024-03-26 | 浙江湃肽生物有限公司 | 一种索玛鲁肽钠盐及其制备方法与应用 |
| CN114316021A (zh) * | 2021-12-29 | 2022-04-12 | 江苏诺泰澳赛诺生物制药股份有限公司 | 一种特立帕肽及的纯化方法 |
| WO2025032376A1 (en) * | 2023-08-04 | 2025-02-13 | Precise Biopharma Pvt Ltd | A room temperature stable solution for injection of abaloparatide |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
| JPH0669956B2 (ja) | 1988-09-30 | 1994-09-07 | 旭化成工業株式会社 | ポリペプタイド類の吸着防止剤 |
| NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
| JP2662842B2 (ja) | 1991-12-09 | 1997-10-15 | 旭化成工業株式会社 | パラサイロイドホルモンの安定化組成物 |
| US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| DE19538687A1 (de) * | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
| ZA9811127B (en) * | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| JPH11235390A (ja) * | 1997-12-12 | 1999-08-31 | Takeda Chem Ind Ltd | 経皮透過方法 |
| HUP0100075A2 (hu) * | 1997-12-18 | 2001-05-28 | Eli Lilly And Co. | Kristályos teriparatid |
| SE9801495D0 (sv) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
| IL147731A0 (en) | 2000-05-19 | 2002-08-14 | Bionebraska Inc | Peptide pharmaceutical formulations |
| KR100782606B1 (ko) * | 2000-10-09 | 2007-12-06 | 일라이 릴리 앤드 캄파니 | 부갑상선 호르몬 투약을 위한 펜 장치 |
| DE10116552A1 (de) * | 2001-04-03 | 2002-10-10 | Abc Armbruster Biochemicals | Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe |
| US20040156835A1 (en) * | 2001-05-30 | 2004-08-12 | Taiji Imoto | Protein preparation |
| US6896894B2 (en) * | 2001-10-30 | 2005-05-24 | Battelle Memorial Institute | Proteins stabilized with polysaccharide gums |
| US20040242489A1 (en) * | 2001-11-05 | 2004-12-02 | Mitlak Bruce Howard | Method for improving stability of a bone-connecting implant |
| JP4252260B2 (ja) * | 2002-06-05 | 2009-04-08 | 旭化成ファーマ株式会社 | Ｐｔｈの安定化水溶液注射剤 |
| AU2004216298B2 (en) * | 2003-02-28 | 2009-04-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
| US20050032698A1 (en) * | 2003-07-14 | 2005-02-10 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| JP4707327B2 (ja) | 2004-01-27 | 2011-06-22 | 旭化成ファーマ株式会社 | ポリペプタイド類の吸着防止剤 |
| MXPA06012980A (es) * | 2004-05-10 | 2007-06-12 | Nastech Pharm Co | Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea. |
| CN100566669C (zh) * | 2004-05-13 | 2009-12-09 | 阿尔扎公司 | 甲状旁腺激素药物的透皮释放装置 |
| EP1744683B1 (en) * | 2004-05-13 | 2016-03-16 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| WO2006022301A1 (ja) * | 2004-08-24 | 2006-03-02 | Daiichi Asubio Pharma Co., Ltd. | 生理活性ペプチド液状製剤 |
| KR100700869B1 (ko) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| WO2007044375A2 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
| CA2625084A1 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
| JP5522879B2 (ja) * | 2006-01-16 | 2014-06-18 | 旭化成ファーマ株式会社 | 樹脂容器中の生理活性ペプチドの安定性改善方法 |
| EP2056862A2 (en) * | 2006-07-31 | 2009-05-13 | Zelos Therapeutics, Inc. | Parathyroid hormone analogues and uses thereof |
| DK2155874T3 (en) * | 2007-04-09 | 2016-08-01 | Univ Arkansas | FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone |
| WO2009006097A1 (en) * | 2007-06-29 | 2009-01-08 | Johnson & Johnson Regenerative Therapeutics, Llc | Liquid protein formulations comprising gdf-5 for use at elevated temperatures |
| EP2052736A1 (en) * | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
| BRPI0911048A2 (pt) * | 2008-04-14 | 2015-12-29 | Atrm Llc | formulações líquidas tamponadas de gdf-5 |
| WO2010030670A2 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| CA2737045C (en) * | 2008-11-20 | 2017-11-14 | Bruce Kabakoff | Therapeutic protein formulations |
| JP2009091363A (ja) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Ｐｔｈの安定化水溶液注射剤 |
| US8481678B2 (en) | 2009-03-30 | 2013-07-09 | E I Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
| WO2011011675A1 (en) * | 2009-07-23 | 2011-01-27 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| KR20190095552A (ko) * | 2009-09-09 | 2019-08-14 | 아사히 가세이 파마 가부시키가이샤 | 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 |
| WO2011139838A2 (en) | 2010-04-28 | 2011-11-10 | Zelos Therapeutics, Inc. | Intranasal formulations |
| WO2012075375A1 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
| CN105853348B (zh) | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
| ES2833277T3 (es) | 2011-06-07 | 2021-06-14 | Asahi Kasei Pharma Corp | Preparación liofilizada que contiene PTH de alta pureza y método para producirla |
| US9241869B2 (en) * | 2011-10-25 | 2016-01-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US20150011473A1 (en) * | 2012-01-20 | 2015-01-08 | Lupin Limited | Stabilized pth formulation |
| CA2870126C (en) * | 2012-04-09 | 2020-10-27 | Daiichi Sankyo Company, Limited | Anti-fgfr2 antibody |
| CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
| MA54716A (fr) * | 2014-10-23 | 2021-11-17 | Amgen Inc | Réduction de la viscosité de formulations pharmaceutiques |
| CN108025042A (zh) * | 2015-07-06 | 2018-05-11 | 董正欣 | PTHrP类似物的新型制剂 |
| JP6634758B2 (ja) * | 2015-09-25 | 2020-01-22 | ニプロ株式会社 | 液体組成物及び凍結乾燥製剤 |
| JP6641870B2 (ja) * | 2015-10-14 | 2020-02-05 | ニプロ株式会社 | パラサイロイドホルモン類含有製剤の製造方法 |
| JP2018188399A (ja) * | 2017-05-10 | 2018-11-29 | ニプロ株式会社 | テリパラチドのプレフィルドシリンジ製剤 |
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
-
2018
- 2018-09-20 JP JP2018558440A patent/JP6577683B2/ja active Active
- 2018-09-20 CN CN202311111773.2A patent/CN116898955A/zh active Pending
- 2018-09-20 EP EP18859204.2A patent/EP3685849A4/en not_active Withdrawn
- 2018-09-20 US US16/649,254 patent/US20200289621A1/en not_active Abandoned
- 2018-09-20 CN CN201880053788.9A patent/CN110996988A/zh active Pending
- 2018-09-20 CA CA3075977A patent/CA3075977A1/en active Pending
- 2018-09-20 WO PCT/JP2018/034887 patent/WO2019059302A1/ja not_active Ceased
-
2019
- 2019-01-22 JP JP2019008797A patent/JP6714738B2/ja active Active
- 2019-01-22 JP JP2019008790A patent/JP6585317B2/ja active Active
- 2019-03-06 JP JP2019040987A patent/JP6826140B2/ja active Active
- 2019-03-06 JP JP2019041011A patent/JP6817358B2/ja active Active
- 2019-03-25 JP JP2019057398A patent/JP6581741B2/ja active Active
- 2019-03-25 JP JP2019057408A patent/JP6634175B2/ja active Active
- 2019-03-25 JP JP2019057434A patent/JP6646173B2/ja active Active
- 2019-03-25 JP JP2019057412A patent/JP6781790B2/ja active Active
- 2019-03-25 JP JP2019057438A patent/JP2019089865A/ja active Pending
- 2019-04-26 JP JP2019085817A patent/JP6825034B2/ja active Active
- 2019-12-19 JP JP2019228968A patent/JP6739612B2/ja active Active
-
2020
- 2020-03-24 JP JP2020053255A patent/JP6766286B2/ja active Active
- 2020-08-20 JP JP2020139570A patent/JP6818928B2/ja active Active
- 2020-12-03 JP JP2020201121A patent/JP6851536B2/ja active Active
- 2020-12-28 JP JP2020218741A patent/JP6977137B2/ja active Active
-
2021
- 2021-03-09 JP JP2021036829A patent/JP2021088606A/ja active Pending
- 2021-03-19 US US17/206,987 patent/US20210205418A1/en active Pending